Anixa Biosciences(US:ANIX) Benzinga·2025-12-12 09:04Core Viewpoint - Anixa Biosciences Inc. shares experienced a significant increase of 15.21% in after-hours trading following the presentation of final Phase 1 clinical trial data for its investigational breast cancer vaccine [1]. Phase 1 Trial Results - The final data was presented at the 2025 San Antonio Breast Cancer Symposium, showing that the vaccine met all major primary endpoints [2]. - The trial, conducted with the Cleveland Clinic and funded by a U.S. Department of Defense grant, demonstrated that protocol-defined immune responses occurred in 74% of participants [2][3]. - The investigational α-lactalbumin vaccine was reported to be safe and well-tolerated at the maximum tolerated dose [3]. Trial Details - The trial enrolled a total of 35 participants across three cohorts [4]. Next Steps - Anixa Biosciences plans to use the trial data to inform the design of a Phase 2 study, which may include a combination trial with Keytruda for newly diagnosed breast cancer patients [5]. - The Chairman and CEO of Anixa Biosciences expressed anticipation for engaging with regulators to advance plans for the Phase 2 study [5]. Trading Metrics - Anixa Biosciences has a market capitalization of $158 million, with a 52-week stock price range of $2.07 to $5.46 [6]. - Year-to-date, the stock has gained 106.90%, although it closed at $4.80, down 6.43% on Thursday [5][6].